Benefits and risks of treatment with ipilimumab after complete resection of Stage III melanoma
PD-L1 and TMB as biomarkers in the IMvigor211 trial of atezolizumab vs. chemo for bladder cancer
Neoadjuvant therapy with trametinib and dabrafenib in high risk resectable BRAF-mutant melanoma
Rodabe N. Amaria
How do we select the urothelial carcinoma patients who will benefit from checkpoint inhibitors?
Lung cancer immunotherapy response testing: PDL-1, TMB or an alternative?